跳至主要内容
临床试验/NL-OMON51266
NL-OMON51266已完成4 期

The Effect of Enzalutamide on Oxycodone Metabolism in Men with Prostate Cancer - ENZYME

Deventer Ziekenhuis0 个研究点目标入组 27 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
27

研究概览

简要总结

Trial is onging in other countries

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Males aged >= 18 years;
  • - Diagnosed prostate cancer;
  • - Treated with enzalutamide 160 mg once daily for 40 days (arm 1)

排除标准

  • - a body mass index (BMI) outside the range of 18 to 30 kg/m2;
  • - known metastases in the liver that would affect drug metabolism;
  • - Child-Pugh classification B or C that would affect drug metabolism;
  • - known CYP3A4 or CYP2D6 polymorphisms that would affect drug metabolism
  • (patients with a known CYP3A4 or CYP2D6 polymorphism afterwards will be
  • - known moderate-severe renal dysfunction (GFR <60 ml/min/1.73m2) that would
  • affect drug metabolism;
  • - gastrointestinal disorders that would potentially alter absorption;
  • - previous gastric bypass or gastric band surgery;
  • - known allergy, hypersensitivity or intolerance to normal-release oxycodone;
  • - a history of drug abuse or treatment for abuse;
  • - dose-reduction or >=5 successive days of treatment interruption of
  • enzalutamide within 40 days prior to the study day (arm 1);
  • - treatment with enzalutamide within 40 days prior to the study day (arm 2);
  • - use of oxycodone normal-release within 24 hour prior to oxycodone intake or
  • use of oxycodone extended-release within 2 days prior to oxycodone intake;
  • - use of other medication that would affect oxycodone metabolism, see section
  • 5.2 and appendix B of the study protocol;
  • - use of other medication that would affect enzalutamide metabolism, see
  • section 5.2 and appendix B of the study protocol (arm 1).

研究者

相似试验